Go Pro
OTCMKTS:GNNSF

Genscript Biotech (GNNSF) Stock Price, News & Analysis

Genscript Biotech logo
C$3.24 +0.14 (+4.52%)
As of 01:59 PM Eastern

About Genscript Biotech Stock (OTCMKTS:GNNSF)

Advanced

Key Stats

Today's Range
C$3.24
C$3.24
50-Day Range
C$1.50
C$3.24
52-Week Range
C$1.30
C$3.24
Volume
1,300 shs
Average Volume
5,192 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries. In parallel, GenScript delivers biologics process development and manufacturing under current Good Manufacturing Practice (cGMP) standards, offering fermentation, cell culture and downstream purification capabilities for both viral and non-viral products. Its antibody discovery arm leverages phage display and hybridoma technologies, supported by on-site analytical characterization and bioassay development.

Headquartered in Piscataway, New Jersey, and Nanjing, China, GenScript operates a network of research and production facilities across North America, Europe and Asia. The company holds numerous quality certifications, including ISO 9001 and cGMP compliance, reflecting its commitment to regulatory standards. Over nearly two decades, GenScript has expanded through strategic investments in automation and bioinformatics, positioning itself as a one-stop partner for organizations pursuing novel therapeutics and diagnostic reagents.

AI Generated. May Contain Errors.

Receive GNNSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genscript Biotech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GNNSF Stock News Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Headlines

GNNSF Stock Analysis - Frequently Asked Questions

Genscript Biotech's stock was trading at C$1.67 at the start of the year. Since then, GNNSF stock has increased by 94.6% and is now trading at C$3.24.

Shares of GNNSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:GNNSF
CIK
N/A
Fax
N/A
Employees
6,937
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:GNNSF) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners